Provided by Tiger Trade Technology Pte. Ltd.

Tredegar

7.63
+0.09001.19%
Volume:8.61K
Turnover:65.60K
Market Cap:266.37M
PE:7.94
High:7.69
Open:7.69
Low:7.57
Close:7.54
52wk High:9.66
52wk Low:6.25
Shares:34.91M
Float Shares:27.54M
Volume Ratio:0.65
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9604
EPS(LYR):0.9604
ROE:12.12%
ROA:6.25%
PB:1.23
PE(LYR):7.94

Loading ...

Tredegar Corporation Appoints David Parks to Board of Directors

Reuters
·
Feb 10

TG Metals Files Patent for Enhanced Lithium Recovery Technology

TIPRANKS
·
Feb 09

TG-17, Inc. trading resumes

TIPRANKS
·
Feb 06

TG Metals Drilling Confirms Gold Continuity and Growth Potential at Van Uden

TIPRANKS
·
Feb 04

TG Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Feb 03

Tredegar Corporation Files Initial Beneficial Ownership Statement for Controller Paul Goldschmiedt

Reuters
·
Jan 29

TG Metals Confirms High-Grade Gold Continuity at Van Uden and Expands Gold City Prospect

TIPRANKS
·
Jan 28

Major Tredegar Insiders Quietly Unload Matching Blocks of Shares

TIPRANKS
·
Jan 27

10% Owner James T. Gottwald Reports Disposal of Tredegar Corporation Common Shares

Reuters
·
Jan 26

Major Tredegar Insiders Quietly Unload a Wave of Shares

TIPRANKS
·
Jan 22

10% Owner William M. Gottwald Reports Disposal of Tredegar Corporation Common Shares

Reuters
·
Jan 22

TG Metals Upgrades Van Uden Drill Result as New Gold Discovery Extends Strike

TIPRANKS
·
Jan 20

TG Metals Extends Van Uden Gold Deposit with New Discovery to the South

TIPRANKS
·
Jan 20

TG Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Jan 15

TG Therapeutics price target raised to $39 from $37 at Goldman Sachs

TIPRANKS
·
Jan 15

TG Therapeutics Stock Climbs After The Bell: Here's Why

Benzinga
·
Jan 14

TG Therapeutics Announces Strong 2025 BRIUMVI Revenue Outlook

TIPRANKS
·
Jan 14

TG Therapeutics Issues 2026 Revenue Outlook; Shares Rise After Hours

MT Newswires Live
·
Jan 14

TG Therapeutics reports preliminary Q4 revenue $182M, consensus $182.38M

TIPRANKS
·
Jan 14

TG Therapeutics sees FY26 revenue $875M-$900M, consensus $895.63M

TIPRANKS
·
Jan 14